Ethylbiscoum acetate

Structural formula
General
Non-proprietary name	Ethylbiscoum acetate
other names	Bis (4-hydroxy-2-oxo-2 H -chromen-3-yl) -acetic acid ethyl ester; Ethyl 2,2-bis (4-hydroxy-2-oxo-2 H -chromen-3-yl) acetate; Tromexan;
Molecular formula	C 22 H 16 O 8
Brief description	bimorph crystals
External identifiers / databases
EC number	208-940-5
ECHA InfoCard	100.008.128
PubChem	11047
ChemSpider	10579
DrugBank	DB08794
Wikidata	Q426269
Drug information
ATC code	B01 AA08
Drug class	Anticoagulants
Mechanism of action	Vitamin K antagonist
properties
Molar mass	408.35 g · mol -1
Physical state	firmly
Melting point	177-182 ° C and 154-157 ° C, respectively
pK s value	3.1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
Toxicological data	750 mg kg −1 ( LD 50 , mouse , oral ) ; 840 mg kg −1 ( LD 50 , rat , oral ) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Ethylbiscoumacetat is the international non-proprietary name of bis (4-hydroxy-2-oxo-2 H -chromen-3-yl) -acetic acid ethyl ester, a chemical compound from the group of 4-hydroxycoumarins with an anticoagulant effect. It was marketed under the trade name Tromexan by the Swiss pharmaceutical company JR Geigy in the 1950s .

chemistry

Ethylbiscoumacetat crystallizes in two different forms ( bimorphism ), which differ in their melting point.

Clinical information

Application areas (indications)

It is used for controlled anticoagulation, for example in treatment or as a precaution against a tendency to thrombotic diseases.

Adverse effects (side effects)

As a possible side effect, ethylbiscoum acetate can relieve bleeding and hematomas due to its inhibition of coagulation , but fever, nausea and diarrhea or rashes of the skin can also occur .

Pharmacological properties

Mechanism of action (pharmacodynamics)

It exerts its protein anticoagulation by inhibiting the enzymatic reduction of Vitamin K . It works just like other coumarin variants , such as acenocumarol , dicoumarol or warfarin .

Absorption and distribution in the body (pharmacokinetics)

Ethylbiscoum acetate is ingested orally and is ultimately largely absorbed by the body. In the bloodstream it binds and changes 95% of the proteins of the blood plasma , and finally it is broken down again in the liver.

literature

Article in the pharmaceutical newspaper
Hager's Handbook of Pharmaceutical Practice, Volume 7, p. 125 ( limited preview in Google book search).

Individual evidence

↑ ^a ^b ^c ^d ^e ^f Entry on Ethylbiscoumacetat. In: Römpp Online . Georg Thieme Verlag, accessed on March 6, 2011.
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[roempp-1] ↑ ^a ^b ^c ^d ^e ^f Entry on Ethylbiscoumacetat. In: Römpp Online . Georg Thieme Verlag, accessed on March 6, 2011.

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.